U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07065630) titled 'Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer' on June 02.
Brief Summary: The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma
.
Study Start Date: Jan. 17, 2026
Study Type: INTERVENTIONAL
Condition:
Head and Neck Cancer
HPV
Intervention:
DRUG: Volrustomig
500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.
DRUG: Carboplatin
100mg/m2 IV day 1 and day 8.
DRUG: Paclitaxel
AU...